Investors & Media

Corporate Profile

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.

We have initiated a Phase 3 clinical trial for the treatment of erosive GERD, a Phase 2 trial to evaluate various doses of vonoprazan as an on-demand therapy for patients with nonerosive reflux disease (NERD), and released topline results from a Phase 3 clinical trial for the treatment of H. pylori infection.

Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

October 18, 2021

Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phases Vonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID ® ), a proton pump inhibitor (PPI) Vonoprazan demonstrated superior...

September 27, 2021

Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACID ® ) 30 mg, a proton pump inhibitor (PPI) FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late...

September 20, 2021

FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million term loan...